New acid blocker may beat standard drug for Post-Banding ulcers in cirrhosis
NCT ID NCT07608536
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether vonoprazan, a newer acid-blocking drug, is better than rabeprazole at preventing ulcers and bleeding after endoscopic variceal band ligation (EVL) in people with cirrhosis. About 300 adults with esophageal varices will take one of the two drugs daily for two weeks. After treatment, doctors will use an endoscope to measure ulcer size and count. The goal is to see which drug more effectively reduces ulcer-related complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vonoprazan and Rabeprazole
What this could lead to
If vonoprazan works better, it could offer a more effective way to prevent bleeding ulcers after variceal band ligation in people with cirrhosis.
What could go wrong
This is a phase 3 trial, but it's still early to know if vonoprazan is truly better. The study only follows patients for 2 weeks, so long-term benefits or risks are not assessed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
King George Medical University
Lucknow, Uttar Pradesh, 226003, India
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••